BEOVU potential risk to the fetus
There are two BEOVU forms:
Use BEOVU for all adult patients receiving Beovu.
Ask women of child-bearing age to also sign BEOVU.Possible risk for the fetus.
The BEOVU prescribing label states that there is a possible risk to the fetus from this and other anti-VEGF drugs.
It should only be used in women of childbearing age if the possible benefit for the woman is greater than the potential risk to the fetus.
BEOVU
There are two BEOVU forms
Use BEOVU for all adult patients receiving BEOVU. This form was updated on 3/13/20 to add retinal arterial occlusion to the list of complications.
Ask women of child-bearing age to sign Beovu.Possible risk for the fetus about the possible risk to the fetus. The BEOVU prescribing label states that there is a possible risk to the fetus from this and other anti-VEGF drugs. It should only be used in women of childbearing age if the possible benefit for the woman is greater than the potential risk to the fetus.
Review our risk management recommendations on the use of anti-VEGF drugs in adults.
AntiVEFG drugs for adults addresses on- and off-label use, preventing endophthalmitis, informed consent issues, and documentation. It incorporates key guidelines on intravitreal injection published by a panel of experts. It also addresses the FDA warning about Avastin in more detail.
Conduct a time out before each intravitreal injection.
OMIC has received reports of “wrong” events associated with intravitreal injections. These include wrong patient, wrong eye, wrong condition, wrong drug, and wrong dose.
To ensure that the correct drug and dose are injected into the correct eye every time, the ophthalmologist needs to lead a time out. Time-out before intravitreal injections/ provides the opportunity to confirm that the patient, medical record, and ophthalmologist are in agreement.
OMIC in the News
Let’s focus on coming together in recovery and optimism for our future. From everyone at OMIC, we thank you for your continued support of our great company. In the news: OMIC receives major industry award. (Details to come!) Check out the News from AAO 2020 virtual meeting. Learn about Expanded cyber liability insurance benefits
.
A Review of OMIC Online Resources
OMIC celebrated its 30-year anniversary in 2018. We continue to develop online educational resources for staff and physicians. Some of the topics include: Time out for Intravitreal Injections, Surgical Checklists, Identifying and Managing Difficult Patients, Telephone Screening for Staff, and toolkits for noncompliance and termination.
OMIC has published over 85 consent forms available for download on the OMIC website, and teaching videos on our YouTube channel at OMIC YouTube. In addition, OMIC partners with NAS to provide online cyber security resources.
Access these resources to protect your patient and practice.
Resources
Identifying and Managing Difficult Patients
Call the OMIC Hotline for confidential advice on any risk management issue. We’re here to help!
Digest Vol 29 No 1 2019
Ophthalmologists examine many patients who are taking systemic medications that can cause ocular toxicity and a temporary decrease in visual acuity, or at worst, irreversible blindness.
Ophthalmologists may be the first clinicians to note adverse effects, or be asked to monitor for them. This issue of the Digest will review closed claims involving hydroxychloroquine, ethambutol, gentamicin, and amiodarone, and suggest risk reduction strategies for ophthalmic practices to implement.
